The Role of Mineralocorticoid Receptor Antagonists in Patients with American College of Cardiology/American Heart Association Stage B Heart Failure

被引：4
作者：
Pitt, Bertram [1 ]
机构：
[1] Univ Michigan, Sch Med, Univ Hosp, Ctr Cardiovasc, Ann Arbor, MI 48109 USA
来源：
HEART FAILURE CLINICS | 2012年 / 8卷 / 02期
关键词：
ACC/AHA; Heart failure; Mineralocorticoid; Left ventricular hypertrophy; ACUTE MYOCARDIAL-INFARCTION; RESISTANT HYPERTENSION; PRIMARY ALDOSTERONISM; PLASMA-ALDOSTERONE; ANGIOTENSIN-II; NADPH OXIDASE; SPIRONOLACTONE; EPLERENONE; DYSFUNCTION; MORTALITY;
D O I：
10.1016/j.hfc.2011.11.001
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
This article focuses on the potential role of mineralocorticoid receptor antagonists (MRAs) in patients with stage B heart failure (HF) due to hypertension, diabetes mellitus, and/or visceral obesity with the metabolic syndrome. It briefly discusses the role of MRAs in patients with left ventricular dilatation due to nonischemic or ischemic cardiomyopathy and in those with a prior myocardial infarction but without left ventricular dilatation or evidence of HF.
引用
收藏
页码：247 / +
页数：8
相关论文
共 48 条
  • [1] Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial
    Beygui, Farzin
    Vicaut, Eric
    Ecollan, Patrick
    Machecourt, Jacques
    Van Belle, Eric
    Zannad, Faiez
    Montalescot, Gilles
    [J]. AMERICAN HEART JOURNAL, 2010, 160 (04) : 642 - U274
  • [2] Impaired 11-β hydroxysteroid dehydrogenase type 2 activity in sweat gland ducts in human essential hypertension
    Bocchi, B
    Kenouch, S
    Lamarre-Cliche, M
    Muffat-Joly, M
    Capron, MH
    Fiet, J
    Morineau, G
    Azizi, M
    Bonvalet, JP
    Farman, N
    [J]. HYPERTENSION, 2004, 43 (04) : 803 - 808
  • [3] Renin-angiotensin-aldosterone system and myocardial fibrosis
    Brilla, CG
    [J]. CARDIOVASCULAR RESEARCH, 2000, 47 (01) : 1 - 3
  • [4] Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src
    Callera, GE
    Touyz, RM
    Tostes, RC
    Yogi, A
    He, Y
    Malkinson, S
    Schiffrin, EL
    [J]. HYPERTENSION, 2005, 45 (04) : 773 - 779
  • [5] Effect of spironolactone on blood pressure in subjects with resistant hypertension
    Chapman, Neil
    Dobson, Joanna
    Wilson, Sarah
    Dahlof, Bjorn
    Sever, Peter S.
    Wedel, Hans
    Poulter, Neil R.
    [J]. HYPERTENSION, 2007, 49 (04) : 839 - 845
  • [6] Spironolactone impairs endothelial function and heart rate variability in patients with Type 2 diabetes
    Davies, JI
    Band, M
    Morris, A
    Struthers, AD
    [J]. DIABETOLOGIA, 2004, 47 (10) : 1687 - 1694
  • [7] Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients
    Duprez, DA
    De Buyzere, NL
    Rietzschel, ER
    Taes, Y
    Clement, DL
    Morgan, D
    Cohn, JN
    [J]. EUROPEAN HEART JOURNAL, 1998, 19 (09) : 1371 - 1376
  • [8] Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials
    Ezekowitz, Justin A.
    McAlister, Finlay A.
    [J]. EUROPEAN HEART JOURNAL, 2009, 30 (04) : 469 - 477
  • [9] Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure
    Farquharson, CAJ
    Struthers, AD
    [J]. CIRCULATION, 2000, 101 (06) : 594 - 597
  • [10] RALES, EPHESUS and redox
    Funder, JW
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2005, 93 (2-5) : 121 - 125
12345